Bronchiolitis Obliterans Syndrome (BOS) Recruiting Phase 2 Trials for Nintedanib (DB09079)

Also known as: Bronchiolitis Obliterans (BO) / Bronchiolitis Obliterans / Obliterative Bronchiolitis / Bronchiolitis Obliterans Syndrome / Obliterating fibrous bronchiolitis (disorder) / Bronchiolitis fibrosa obliterans (disorder) / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0071683 (Bronchiolitis Obliterans Syndrome (BOS))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03805477Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell TransplantationTreatment